SBIR/STTR Research Award

SBIR Phase I: Feasibility of The Use of a Debris Cartridge in an External Drainage Device

Award identifier f8ca3eafc5f79470fe4fd43dce166fa1c23283c772416a9a8a22cac97053a7f5Awarding agency National Science Foundation

Award amount

$149,978

Program and phase

SBIR · Phase I

Award year

2013

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
National Science Foundation
Branch
Not reported
Recipient company
CAMRAS VISION, INC.
Proposal award date
2013-01-01
Contract end date
2013-10-31
UEI
CLLKJRDMUC49
Solicitation number
Not reported
Topic code
BC

Research abstract

This Small Business Innovation Research Phase I project will demonstrate the feasibility of the use of a debris cartridge in an implant to prevent obstruction in debris-releasing glaucomas, such as uveitic, pigment-dispersion, and pseudoexfoliation glaucomas. Glaucoma is a group of chronic eye diseases that result in permanent vision loss for millions of suffers in the US alone. The innovation of this device lies in its potential ability to provide predictable, adjustable and personalize care to minimize disease progression. However, the device requires a filter to prevent infection that may clog overtime, especially with debris-releasing glaucomas. This Phase I research project will test the feasibility of a novel filter to prevent clogging and its safety in an animal model for debris-releasing glaucoma. The validation of the cartridge will provide the option for glaucoma suffers that may have been otherwise excluded from the advantage that this implant would provide. The broader impact/commercial potential of this project will be, if successful, a more effective treatment for patients with an advanced, cumbersome and difficult to treat type of glaucomas. In 2015, the US glaucoma market is estimated to be over $2 billion and our addressable market, glaucoma surgical therapies, is estimated to be $534M. The incidence for glaucoma increases with age, and as the baby boomer population gets older, there will be a growing need for glaucoma treatments. Debris-releasing glaucomas are especially difficult to treat and can affect children. These patients often are required to endure invasive surgeries throughout their lives that are difficult to manage with current therapies. If successful, our novel device and cartridge would radically change the treatment paradigm of glaucoma, providing the first personalized, long lasting, and adjustable therapy that can treat the most advanced cases of glaucoma. Ultimately, the advancements with the filter will minimize the risk of blindness and improve the quality of life for glaucoma patients.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

6 SBIR/STTR records share this UEI (2012–2017). Reported award amounts total $2,375,458. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, National Science Foundation

Agency intelligence

National Science Foundation

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.